The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75 % or more from baseline in the psoriasis area-and-severity index score ( PASI 75 ) and a score of 0 ( clear ) or 1 ( almost clear ) on a 5-point modified investigator 's global assessment ( coprimary end points ) .